IOVA IOVANCE BIOTHERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, IOVANCE BIOTHERAPEUTICS INC reported revenue of $99.3M (up 65.7% from a year earlier), net income of −$47.3M and diluted EPS of −$0.11; over the last four quarters revenue was $325M and net income −$290M; for the fiscal year ended December 2025 revenue was $264M, up 60.6% on the year before.

IOVA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $264M, gross profit n/a, operating income −$403M, net income −$391M (margin -148.4%), EPS −$1.09
• Fiscal year ended Dec 2024: revenue $164M, gross profit n/a, operating income −$395M, net income −$372M (margin -226.9%), EPS −$1.28
• Fiscal year ended Dec 2023: revenue $1.19M, gross profit n/a, operating income −$461M, net income −$444M (margin -37342.3%), EPS −$1.89
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$399M, net income −$396M (margin n/a), EPS −$2.49
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$343M, net income −$342M (margin n/a), EPS −$2.23

IOVA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $99.3M (up 65.7% year over year), net income −$47.3M, EPS −$0.11
• Quarter ended Mar 31, 2026: revenue $71.4M (up 44.8% year over year), net income −$79.0M, EPS −$0.19
• Quarter ended Dec 31, 2025 (from the annual report): revenue $86.8M (up 17.7% year over year), net income −$71.9M, EPS n/a
• Quarter ended Sep 30, 2025: revenue $67.5M (up 15.2% year over year), net income −$91.3M, EPS n/a
• Quarter ended Jun 30, 2025: revenue $60.0M (up 92.7% year over year), net income −$112M, EPS −$0.33
• Quarter ended Mar 31, 2025: revenue $49.3M (up 6798.5% year over year), net income −$116M, EPS −$0.36
• Quarter ended Dec 31, 2024 (from the annual report): revenue $73.7M, net income −$78.6M, EPS −$0.24
• Quarter ended Sep 30, 2024: revenue $58.6M (up 12385.1% year over year), net income −$83.5M, EPS −$0.28
• Quarter ended Jun 30, 2024: revenue $31.1M (up 12969.7% year over year), net income −$97.1M, EPS −$0.34
• Quarter ended Mar 31, 2024: revenue $715K, net income −$113M, EPS −$0.42
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$116M, EPS −$0.46
• Quarter ended Sep 30, 2023: revenue $469K, net income −$114M, EPS −$0.46
• Quarter ended Jun 30, 2023: revenue $238K, net income −$107M, EPS −$0.47
• Quarter ended Mar 31, 2023: revenue n/a, net income −$107M, EPS −$0.50
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$105M, EPS −$0.65
• Quarter ended Sep 30, 2022: revenue n/a, net income −$99.6M, EPS −$0.63
• Quarter ended Jun 30, 2022: revenue n/a, net income −$99.3M, EPS −$0.63
• Quarter ended Mar 31, 2022: revenue n/a, net income −$91.6M, EPS −$0.58
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$99.4M, EPS −$0.64
• Quarter ended Sep 30, 2021: revenue n/a, net income −$86.1M, EPS −$0.55

IOVA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$302M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$353M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$362M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$293M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$228M, share buybacks n/a

IOVA balance sheet

• Jun 30, 2026: cash $111M, total assets $916M, total liabilities $179M, shareholders' equity $736M
• Mar 31, 2026: cash $197M, total assets $926M, total liabilities $204M, shareholders' equity $722M
• Dec 31, 2025: cash $163M, total assets $913M, total liabilities $215M, shareholders' equity $699M
• Sep 30, 2025: cash $158M, total assets $905M, total liabilities $203M, shareholders' equity $702M
• Jun 30, 2025: cash $132M, total assets $907M, total liabilities $209M, shareholders' equity $698M
• Mar 31, 2025: cash $172M, total assets $967M, total liabilities $199M, shareholders' equity $768M
• Dec 31, 2024: cash $116M, total assets $910M, total liabilities $200M, shareholders' equity $710M
• Sep 30, 2024: cash $164M, total assets $991M, total liabilities $218M, shareholders' equity $773M

What is IOVA's revenue?

IOVANCE BIOTHERAPEUTICS INC reported $325M of revenue over its last four quarters, through June 30, 2026.

Is IOVA profitable?

No. IOVANCE BIOTHERAPEUTICS INC lost $290M over the last four quarters.

IOVA ownership and insider trades · All stocks